Does Blue Cross Blue Shield of Minnesota Cover Mounjaro?
The verdict
Conditional on most plans
Blue Cross Blue Shield of Minnesota covers Mounjaro for type 2 diabetes with prior authorization across commercial, ACA, and Medicare Part D lines. BCBS of Minnesota does not cover Mounjaro for weight loss. Minnesota Medicaid covers weight-loss GLP-1s with PA — but only for the on-label weight-loss products (Wegovy, Zepbound), not Mounjaro, which is FDA-approved for diabetes only. The weight-loss tirzepatide is Zepbound, with separate coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield of Minnesota using your member ID.
Key facts
Minnesota Medicaid covers weight-loss GLP-1s (Wegovy, Zepbound) with prior authorization — one of the more generous state Medicaid programs in the country. This weight-loss benefit does not apply to Mounjaro, which is diabetes-only.
Minnesota Department of Human Services, Medicaid PDL
Medica is the other major Minnesota-based plan; both Medica and BCBS Minnesota operate in the MN Medicaid environment and cover Mounjaro for type 2 diabetes with PA.
BCBS of Minnesota / Medica Plan Information
The 2026 Medicare Part D out-of-pocket cap is $2,100. Most Mounjaro users for diabetes who stay on therapy continuously reach this cap within 2–3 months and pay $0 for the rest of the year.
CMS Medicare Part D Redesign, 2026
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield of Minnesota covers Mounjaro depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
BCBS of Minnesota Medicare Advantage and Part D plans cover Mounjaro for type 2 diabetes only — not weight loss — with prior authorization. The 2026 Part D out-of-pocket cap is $2,100; most continuous Mounjaro users for diabetes reach it within 2–3 months and pay $0 for the remainder of the year. The IRA-negotiated Medicare MFN price of $245/month begins mid-2026. Mounjaro is NOT included in the 2026 Medicare GLP-1 Bridge ($50/month), which covers weight-loss-approved products only. The Lilly savings card is not usable by Medicare or Medicaid beneficiaries.
Commercial / Employer
Group & marketplace plans
BCBS of Minnesota commercial and employer-sponsored plans: Mounjaro is covered for type 2 diabetes with prior authorization (A1c 6.5% or higher, metformin trial). Specific tier placement is not publicly confirmed at the drug level — verify on the BCBS Minnesota formulary. Not covered for off-label weight loss under any plan design. ACA/Individual: diabetes only, PA; weight-loss GLP-1s commonly excluded on commercial ACA plans. Minnesota Medicaid: covers weight-loss GLP-1s with PA for the on-label products (Wegovy, Zepbound) — but Mounjaro is diabetes-only and this weight-loss coverage does not apply to it. Lilly savings card: $25/month with commercial coverage; $499/month without (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
The 5 boxes you must tick to get approved
Commercial plans that will consider Mounjaro require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Mounjaro actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Approximately $1,300–$1,560/month retail (WAC ~$1,080). Lilly savings card: $499/month for commercially insured without coverage (max $647/month, up to 13 fills, expires 12/31/2026). Not available to Medicare or Medicaid beneficiaries.
List price with no coverage — before any manufacturer savings card.
With coverage
BCBS Minnesota plan-specific brand cost-share; tier not publicly confirmed at the drug level — verify on the BCBS Minnesota drug lookup. Commercially insured with Mounjaro coverage may pay as little as $25/month via the Lilly savings card. Medicare Part D: 25% coinsurance to the $2,100 OOP cap 2026; MFN $245/month mid-2026. MN Medicaid nominal copay for covered T2D use.
Typical monthly copay once prior authorization is approved.
Bridge program
The 2026 Medicare GLP-1 Bridge ($50/month) covers weight-loss-approved products only; Mounjaro is not included.
Reduced copay through the assistance program, where eligible.
All figures are estimates; confirm cost-share on the BCBS Minnesota drug lookup tool. The Lilly savings card expires 12/31/2026 and is not available to Medicare, Medicaid, or government-program beneficiaries.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Verify Mounjaro coverage on the BCBS Minnesota drug formulary
Visit bluecrossmn.com and use the drug lookup for your specific plan. Confirm that PA is required, look up the current tier and cost-share, and verify the PA criteria. If you are on a Minnesota Medicaid plan through BCBS MN, note that MN Medicaid's weight-loss GLP-1 coverage does not cover Mounjaro — that coverage is for Wegovy and Zepbound.
- 2
Have your prescriber submit a complete prior authorization
Your prescriber must document your T2D diagnosis (ICD-10 E11.x), A1c of 6.5% or greater within ~90 days, and prior metformin trial (plus one additional agent where required). Submit through the BCBS Minnesota PA portal; allow up to 72 hours for a decision.
- 3
If you want tirzepatide for weight loss, ask about Zepbound — not Mounjaro
Minnesota Medicaid covers weight-loss GLP-1s with PA — but for Wegovy and Zepbound, not Mounjaro. If your goal is weight loss, Mounjaro will be denied; the relevant product is Zepbound (tirzepatide for chronic weight management and OSA). Ask your prescriber and BCBS Minnesota specifically about Zepbound coverage, which has a separate PA and coverage track.
Options if Blue Cross Blue Shield of Minnesota won't cover Mounjaro
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide)
FDA-approved for type 2 diabetes. May be on a preferred tier ahead of Mounjaro as step therapy on BCBS Minnesota formularies.
Trulicity (dulaglutide)
FDA-approved for T2D. GLP-1 alternative; often used as a step-therapy agent before Mounjaro approval.
Jardiance (empagliflozin)
SGLT2 inhibitor for T2D with cardiovascular benefits. May be required step therapy before GLP-1 approval on BCBS Minnesota plans.
Zepbound (tirzepatide) — weight loss only
Same molecule as Mounjaro (tirzepatide) but FDA-approved for chronic weight management and OSA. MN Medicaid covers weight-loss GLP-1s with PA — and Zepbound is eligible where Mounjaro is not. Separate coverage track.
Medica (MN alternative)
Medica is another major Minnesota-based plan with a similar standard T2D-with-PA pattern for Mounjaro; verify on plan formulary.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
No. BCBS of Minnesota does not cover Mounjaro for weight loss. Mounjaro is FDA-approved for type 2 diabetes only; the PA is gated on a T2D diagnosis — off-label weight-loss requests are denied. Minnesota Medicaid covers weight-loss GLP-1s with PA, but that applies to Wegovy and Zepbound — the on-label weight-loss products — not Mounjaro.
No, not for weight loss. MN Medicaid covers Mounjaro for type 2 diabetes with prior authorization. MN Medicaid is more generous than most states on weight-loss GLP-1 coverage — it covers Wegovy and Zepbound with PA — but Mounjaro is diabetes-only and does not qualify under the weight-loss benefit. A T2D diagnosis is required for any Mounjaro coverage through MN Medicaid.
Mounjaro and Zepbound are the same active ingredient (tirzepatide) but different FDA approvals: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and obstructive sleep apnea. BCBS of Minnesota covers Mounjaro for diabetes with PA. If you want tirzepatide for weight loss, the relevant product is Zepbound — which has its own, separate PA and coverage pathway, including potential MN Medicaid coverage for weight loss.
No. The 2026 Medicare GLP-1 Bridge ($50/month, July 1 – December 31, 2027) covers weight-loss-approved products only — Wegovy, Foundayo, and the Zepbound KwikPen. Mounjaro is excluded because it is FDA-approved for type 2 diabetes, not weight loss. BCBS Minnesota Medicare plans cover Mounjaro under standard Part D rules for T2D, with PA and the $2,100 annual OOP cap in 2026.
Related Articles
Does Aetna Cover Mounjaro? CVS Caremark Preferred Brand 2026 | Curex
Aetna covers Mounjaro as a preferred brand for type 2 diabetes via CVS Caremark — not weight loss. CVS dropped Zepbound from most formularies mid-2025.
Read moreDoes SelectHealth Cover Mounjaro? Intermountain 2026 | Curex
SelectHealth (Intermountain) covers Mounjaro for type 2 diabetes with PA — not weight loss. UT Medicaid is diabetes-only. Zepbound is the weight-loss twin.
Read moreDoes Regence Cover Mounjaro? ID/OR/UT/WA Guide 2026 | Curex
Regence (BCBS of ID/OR/UT/WA) covers Mounjaro for type 2 diabetes with prior authorization — not weight loss. Medicaid varies by state.
Read moreDoes Blue Cross Blue Shield of Michigan Cover Mounjaro? | Curex
BCBS of Michigan covers Mounjaro for type 2 diabetes with PA, not weight loss. Zepbound weight-loss exclusion upheld by MI DIFS in 2025.
Read moreDoes Wellcare Cover Mounjaro? Part D & Medicaid 2026 | Curex
Wellcare covers Mounjaro for type 2 diabetes under Part D and Medicaid with prior auth — not weight loss. Mounjaro is excluded from the 2026 GLP-1 Bridge.
Read moreDoes Anthem Cover Mounjaro? CarelonRx T2D Guide 2026 | Curex
Anthem covers Mounjaro for type 2 diabetes with prior auth — not weight loss. Zepbound (weight-loss tirzepatide) requires a separate employer benefit.
Read moreInsurance covers Mounjaro only for diabetes — for weight loss, here's a path that skips insurance
You just saw how tangled Mounjaro coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Mounjaro. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Mounjaro and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield of Minnesota before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Mounjaro and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.